Fairview Capital Partners

Covr Financial Technologies, Inc. is a digitally enabled brokerage general agency that specializes in providing life, long-term care, and disability insurance solutions for financial institutions and their clients. Founded in 2016 and based in Boise, Idaho, Covr offers a range of digital platforms, including Covr Advisor for financial advisors, Covr Consumer for banks and credit unions to sell insurance online, and Covr Insights for managing in-force life insurance policies. The company serves over 24,000 financial advisors and approximately 13 million customers across 30 financial institutions, such as wealth management firms and credit unions. Covr's technology empowers financial professionals to address their clients' insurance needs effectively while facilitating direct access to products for consumers. The company has garnered the support of prominent venture capital firms and boasts an advisory board composed of notable leaders from the financial services sector.

Inbox Health is a digital healthcare company that designs a tool to automate bills and give patients additional insights into their charges. Inbox Health's mission is to greatly reduce the administrative waste in healthcare, by streamlining the patient billing and payment experience. Their product is a patient billing and communication platform that uses patient data to tailor a billing process specific to the patient’s situation and behavior patterns.

About Covr Financial Technologies Founded in 2016, Covr offers a full suite of digital life insurance platforms, tools and planning services for financial institutions, including: Covr Advisor for financial advisors, Covr Consumer for offering insurance products directly to customers financial institutions and Covr Insights for inforce policy management. Covr currently serves over 24,000 financial advisors and 13 million customers across 30 financial institutions including wealth management firms, RIAs, IBDs, banks, credit unions, personal finance apps and P&C agencies. Covr’s investors include leading venture capital firms: Nyca Partners, Commerce Ventures, Allianz Life Ventures, Connectivity Capital Partners, Contour Venture Partners, Connecticut Innovations and Fairview Capital. Covr’s Advisory Board includes financial services leaders including Brian Finn, former president of Credit Suisse First Boston; Sallie Krawcheck, CEO of Elevest and formerly at Citigroup and Smith Barney; Hans Morris, managing partner, Nyca Partners, chairman of Lending Club, formerly president of Visa; Brady Dougan, former CEO of Credit Suisse; Gregg Fleming, CEO of Rockefeller Capital, Bob Kerzner, formerly CEO of LIMRA and Joe Plumeri, formerly of Smith Barney, FirstData and Willis Group.

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise.

Fluorous Technology is a platform for synthesis - purification - enrichment - immobilization of molecules. Applications of fluorous technology include Small Molecule Synthesis, Biomolecule Synthesis, and Life Science Applications. Their technology section is designed to introduce you to the fundamentals of fluorous. They'll begin by defining some basic terms in the Fluorous Tags and Media section. Then they'll move to the heart of fluorous, Fluorous Separations. There, they'll discuss how to combine fluorous tags and separation media in a variety of formats. This section will have extensive links to application pages and more detailed technical information. Finally, they'll provide an overview of Fluorous Immobilizations, one of the newest techniques that takes advantage of the unique properties of fluorous tags.